The short answer for most people

For most people with hip osteoarthritis, a corticosteroid injection is the more guideline-backed option if an injection is being considered for short-term pain relief. By contrast, hyaluronic acid is not a routine hip treatment in current guidance: NICE says not to offer intra-articular hyaluronan, the AAOS says it should not be considered for symptomatic hip OA, and the ACR/Arthritis Foundation recommends against it for the hip.

That does not make steroid injections a long-term fix. Guidance is more supportive of corticosteroid than hyaluronic acid, but mainly for symptom relief over the short term; AAOS guidance summarised by AAFP reports improvement in pain and function for at least 4 months, while NICE still describes the broader evidence for corticosteroids in osteoarthritis as inconsistent. In practice, both injections sit in the symptom-control part of treatment rather than cartilage repair. Hyaluronic acid may still come up in selective shared decision-making when an alternative injection is being explored and the likely benefit is accepted as uncertain.

Why hyaluronic acid sits outside routine care

In day-to-day practice, “outside routine care” means something more specific than simply “not banned”. Rather than repeating the headline recommendation, the practical point is that hip hyaluronic acid usually needs a case-by-case reason to be discussed at all, because the mainstream guideline position is sceptical. NICE says not to offer intra-articular hyaluronan, and in 2019 OARSI also did not recommend either hyaluronic acid or corticosteroid injections for hip osteoarthritis, which shows that injection guidance is not perfectly aligned across organisations even when HA is viewed cautiously.

The reason is the evidence signal, not a theoretical impossibility. A 2025 systematic review covering 982 patients found no significant between-group advantage at 3–4 months, even though some within-group improvement was reported; later benefit at 4–6 months appeared more promising for high-molecular-weight HA, suggesting that any effect may be product-specific rather than consistent across the whole class. That helps explain why HA may still arise in a narrower discussion — for example, when a patient wants to avoid steroid and accepts that support is weak — especially as a 2010 trial reported hylan G-F 20 outcomes comparable with methylprednisolone rather than clearly better.

What a steroid injection is more likely to offer

The clearest reason a steroid injection — an intra-articular corticosteroid injection — stays in the conversation is timing. The AAFP summary of AAOS guidance published in 2025 describes improvement in hip osteoarthritis pain and function for at least 4 months, and the 2019 ACR/Arthritis Foundation guideline conditionally recommends glucocorticoid injections over other injection options. That places steroid most firmly in the short-term symptom-control part of care.

Qvistgaard’s 2006 randomised trial gives a good sense of scale: improvement was significant over the 3-month intervention period, which fits temporary relief rather than joint repair or disease reversal. NICE says the broader osteoarthritis evidence is inconsistent, although its guidance still leaves room for a steroid injection when other medicines are ineffective or unsuitable, or to support therapeutic exercise; OARSI in 2019 did not recommend hip steroid injections. Its most defensible role is a short window of symptom relief, not a long-term solution.

What the comparison studies actually show

Set the guidelines to one side for a moment, and the trial picture is less tidy than the headline recommendation suggests. In practical terms, corticosteroids seem more likely to help earlier, but not as a clean win in every study. The 2006 Qvistgaard randomised trial fits the usual short-term steroid story, with improvement over 3 months. But the 2010 Spitzer study did not show hyaluronic acid always trailing behind: hylan G-F 20 produced clinically meaningful pain and function improvement comparable with methylprednisolone acetate.

The newer reviews point in the same mixed direction. A 2025 systematic review covering 982 patients found no significant between-group advantage for hyaluronic acid at 3–4 months, although high-molecular-weight products looked more promising by 4–6 months. A separate 2025 meta-analysis then found no statistically significant difference between corticosteroids and hyaluronic acid at 6 months for overall WOMAC outcomes (p=0.46), and it also found no clear steroid advantage over placebo. So the simplest way to read the evidence is this: steroids still have the stronger mainstream support for short-term relief, but the head-to-head research does not show steroids beating hyaluronic acid consistently across every timeframe or formulation.

When hyaluronic acid might still be discussed

A more concrete use-case is someone who still wants to try an injection, but specifically wants a non-steroid option and accepts a slower, less certain payoff. In that narrow setting, hyaluronic acid may still come up as a selective alternative rather than a default next step. The trial signal is not zero: in Spitzer’s 2010 study, hylan G-F 20 performed comparably with methylprednisolone, and the 2025 hip review found that any possible benefit was more apparent at 4–6 months than at 3–4 months, particularly with higher-molecular-weight products.

That makes the conversation quite specific. HA is being considered for symptom control only, not cartilage repair, and any improvement may be modest rather than dramatic. AAOS, ACR/Arthritis Foundation and NICE do not support routine hip HA use, so the trade-off is plain: it may still be discussed when steroid is not the preferred injection, but only with clear expectations about weak guideline support and uncertain benefit.

How to decide what to do next

The practical choice usually comes down to the job the injection is meant to do. If the aim is short-term relief while other treatment is being progressed, corticosteroid is usually the first injection discussed: NICE says to consider it in selected circumstances, the 2019 ACR/Arthritis Foundation guideline conditionally favours intra-articular glucocorticoids over other injections, and AAOS guidance summarised by AAFP reports pain and function benefit for at least 4 months. If the question is which option has the stronger routine support in 2025, steroid still sits ahead of hyaluronic acid.

The final decision point is not simply "steroid or HA", but whether either injection fits the wider hip plan. Where HA is preferred as a non-steroid option, the discussion should be explicit that NICE says not to offer intra-articular hyaluronan routinely, and that the 2025 pooled evidence found mixed results rather than a clear advantage over steroid at 6 months. In practice, that means setting any injection alongside exercise-based care, pain relief, and further assessment or imaging if the diagnosis or pain source is still in doubt. If an individual review would help, appointments can be booked online without referral at mskdoctors.com.

1. [1] OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. (2019). https://doi.org/10.1016/j.joca.2019.06.011 https://doi.org/10.1016/j.joca.2019.06.011